European Medical Agency has recommended the First Ebola vaccine for conditional marketing sanction to the European Commission. The drug is termed as rVSV-ZOBOV-GP vaccine. It has saved many lives affected by the Ebola virus. The world’s first Ebola vaccine has been developed by Merck & Co based in the US. The drug has proved to be quite effective in preventing the spread of Ebola under emergency guidelines. The Drug has been in use across the Democratic Republic of Congo. EMA evaluates the drugs manufactured by pharmaceutical firms in the US. The final licensing of the medicines depends on the European Commission. World Health Organization (WHO) is also planning to move ahead with the pre-qualification of the drug. A fast track system of drug regulators is also reviewing the vaccine in the United States.
Experts across the globe have collaborated to come up with the world’s first Ebola Vaccine to prevent the outbreak. Experts have gone the extra mile to review the data based on various vaccine trials. Work Health Organization and African regulators have come together during EMA review. This collaboration will surely help in registration of the countries most at risk. The Random trial of the drug started in 2015 during the West Africa Ebola outbreak. At that time, no other organization has taken a step forward to hold a trial in Guinea during a complex emergency. WHO and Guinea government took the lead and started the trial for the Ebola vaccine.
More than 2,100 people have died due to the Congo Ebola outbreak since the middle of last year. It is said to be the second-largest Ebola outbreak in history. More than 11,300 people have lost their lives due to this epidemic in West Africa from 2013 to 2016. Currently, around eight vaccines are undergoing a clinical evaluation. WHO has also initiated a roadmap to accelerate the prequalification. They are also putting the best foot forward for the licensing of the vaccine. As of now, the drug will be used under a research protocol. The licensed vaccine will only be available in mid-2020